These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18525257)

  • 1. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir.
    Sagot-Lerolle N; Lamine A; Chaix ML; Boufassa F; Aboulker JP; Costagliola D; Goujard C; Pallier C; Delfraissy JF; Lambotte O;
    AIDS; 2008 Jun; 22(10):1125-9. PubMed ID: 18525257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
    Routy JP; Tremblay CL; Angel JB; Trottier B; Rouleau D; Baril JG; Harris M; Trottier S; Singer J; Chomont N; Sékaly RP; Boulassel MR
    HIV Med; 2012 May; 13(5):291-6. PubMed ID: 22276680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART.
    Calcaterra S; Cappiello G; Di Caro A; Garbuglia AR; Benedetto A
    J Infect; 2001 Nov; 43(4):239-45. PubMed ID: 11869061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
    J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New research finds possible treatment for latent HIV. Valproic acid used to deplete HIV.
    AIDS Alert; 2005 Dec; 20(12):136-8. PubMed ID: 16397938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
    Negredo E; Puigdomènech I; Marfil S; Puig J; Pérez-Alvarez N; Ruiz L; Rey-Joly C; Clotet B; Blanco J
    J Antimicrob Chemother; 2008 Feb; 61(2):400-4. PubMed ID: 18083750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment.
    Sarmati L; Andreoni C; Nicastri E; Tommasi C; Buonomini A; D'Ettorre G; Corpolongo A; Dori L; Montano M; Volpi A; Narciso P; Vullo V; Andreoni M
    J Med Virol; 2009 Mar; 81(3):481-7. PubMed ID: 19152399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
    Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
    J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
    Cohen J
    Science; 2005 Aug; 309(5737):999-1000. PubMed ID: 16099956
    [No Abstract]   [Full Text] [Related]  

  • 11. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
    Siliciano JD; Lai J; Callender M; Pitt E; Zhang H; Margolick JB; Gallant JE; Cofrancesco J; Moore RD; Gange SJ; Siliciano RF
    J Infect Dis; 2007 Mar; 195(6):833-6. PubMed ID: 17299713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
    Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.
    Tincati C; Biasin M; Bandera A; Violin M; Marchetti G; Piacentini L; Vago GL; Balotta C; Moroni M; Franzetti F; Clerici M; Gori A
    Antivir Ther; 2009; 14(3):321-30. PubMed ID: 19474466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART.
    Maggiolo F; Airoldi M; Callegaro A; Martinelli C; Dolara A; Bini T; Gregis G; Quinzan G; Ripamonti D; Ravasio V; Suter F
    AIDS; 2009 Apr; 23(7):799-807. PubMed ID: 19114869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid: a potential role in treating latent HIV infection.
    Routy JP
    Lancet; 2005 Aug 13-19; 366(9485):523-4. PubMed ID: 16099272
    [No Abstract]   [Full Text] [Related]  

  • 16. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
    Archin NM; Eron JJ; Palmer S; Hartmann-Duff A; Martinson JA; Wiegand A; Bandarenko N; Schmitz JL; Bosch RJ; Landay AL; Coffin JM; Margolis DM
    AIDS; 2008 Jun; 22(10):1131-5. PubMed ID: 18525258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
    J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.